Global Lung Cancer Screening Software Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

폐암 검진 소프트웨어 시장 분석

폐암 검진 소프트웨어 시장은 AI 기반 진단 도구의 발전과 폐암 조기 발견에 대한 필요성 증가로 인해 상당한 성장을 경험하고 있습니다. 저선량 CT 스캔의 채택 증가와 영상 정확도를 향상시키는 소프트웨어가 결합되어 진단 워크플로가 개선되고 거짓 양성이 감소하고 있습니다. 주요 개발에는 데이터 관리 및 실시간 분석을 위한 클라우드 기반 플랫폼과의 통합이 포함되어 의료 서비스 제공자가 환자 데이터를 보다 효과적으로 추적할 수 있습니다. FDA의 AI 기반 검진 도구 승인과 같은 규제 지원은 시장 확장을 더욱 촉진합니다. 또한 전 세계적으로 폐암 유병률이 증가하고 조기 검진 프로그램에 대한 인식이 높아짐에 따라 고급 검진 소프트웨어 솔루션에 대한 수요가 증가하고 있습니다.

폐암 검진 소프트웨어 시장 규모

글로벌 폐암 검진 소프트웨어 시장 규모는 2023년에 396억 9천만 달러로 평가되었으며, 2031년까지 1,639억 8천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 19.40%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

폐암 검진 소프트웨어 시장 동향

“ 스크리닝 솔루션에 인공지능(Ai) 통합 확대”

폐암 검진 소프트웨어 시장은 고급 진단 도구와 조기 발견 기술에 대한 수요 증가에 힘입어 상당한 성장을 경험하고 있습니다. 시장을 형성하는 주요 트렌드는 인공 지능 (AI)을 검진 솔루션에 통합하여 폐 결절을 탐지하는 정확성과 효율성을 높이는 것입니다. 예를 들어, Thynk Health와 같은 회사는 Infervision과 협력하여 AI를 통합하여 폐 결절 관리를 개선하여 더 빠른 진단과 더 나은 환자 결과를 실현했습니다. 이러한 트렌드는 특히 폐암 유병률이 높은 지역에서 채택을 가속화하고 있습니다. AI 기반 소프트웨어 솔루션은 워크플로를 간소화하고 거짓 양성을 줄여 폐암 검진을 보다 신뢰할 수 있게 만듭니다. 의료 서비스 제공자가 최첨단 기술에 계속 투자함에 따라 폐암 검진 소프트웨어에 대한 수요는 증가할 것으로 보이며, Aidence, Incepto, Thirona가 유럽 전역에서 검진 프로그램을 확대하기 위한 공동 노력과 같은 이니셔티브에 의해 더욱 촉진될 것입니다.

보고서 범위 및 폐암 검진 소프트웨어 시장 세분화         

Lung Cancer Screening Software Market Definition

Lung cancer screening software is a specialized diagnostic tool designed to assist healthcare professionals in detecting and managing lung cancer at an early stage. It integrates advanced technologies such as artificial intelligence (AI) and computer-aided detection (CAD) to analyze medical images, including CT scans and chest radiographs, for identifying lung nodules or abnormalities. The software enhances accuracy, improves workflow efficiency, and reduces false-positive results, making it a vital component in screening programs. By facilitating early detection, lung cancer screening software plays a crucial role in improving patient outcomes and supporting timely interventions in lung cancer care.

Lung Cancer Screening Software Market Dynamics

Drivers

• Rising Incidence of Lung Cancer

The rising incidence of lung cancer is significantly driving the demand for effective treatment options, with 10 million cancer death cases in 2022 or nearly one in six deaths , according to the World Health Organization (WHO). Such increasing prevalence is attributed to factors including smoking, environmental pollution, and occupational exposure to carcinogens. In response, there is a growing demand for more advanced treatments, including targeted therapies, immunotherapies, and precision medicine. For instance, drugs targeting genetic mutations such as EGFR, ALK, and KRAS have become essential in personalized treatment plans, improving patient outcomes. This surge in innovative treatment development is emerging as a critical market driver, propelling the growth of the lung cancer therapeutics sector.

• Enhancing Lung Cancer Screening Efficiency

Enhanced lung cancer screening efficiency has been significantly bolstered by technological advancements in imaging, particularly with the widespread use of low-dose CT (LDCT) scans. Studies show that LDCT can reduce lung cancer mortality by up to 20% compared to traditional chest X-rays, according to the National Lung Screening Trial (NLST). These imaging technologies enable earlier detection of lung cancer, often at a more treatable stage, by providing detailed cross-sectional images of lung tissues. Such innovations in imaging are driving increased adoption of screening programs globally, propelling lung cancer screening software market growth.

Opportunities

• Rising Trend of Telemedicine in Remote Areas

The rising trend of telemedicine in remote areas is transforming healthcare access and delivery, addressing significant gaps in medical services. According to a 2023 report by the World Health Organization, over 4.5 billion people globally lack access to essential health services, with many residing in rural and underserved regions. Telemedicine has emerged as a viable solution, allowing patients to consult healthcare providers through video calls, phone consultations, and mobile health applications, thereby eliminating geographical barriers. In addition, initiatives such as the U.S. Federal Communications Commission's Rural Health Care Program have expanded broadband access, further facilitating telehealth services. Such trend enhances patient engagement and reduces healthcare costs, ultimately creating numerous opportunities in the market.

• Enhancing Diagnostics through Multimodal Imaging Integration

Enhanced diagnostics through the integration of multimodal imaging are revolutionizing the approach to disease detection and management. Multimodal imaging combines various imaging modalities, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), to provide a more comprehensive view of patient health. For instance, a study published in the National Library of Medicine highlights that combining PET and CT imaging significantly improves the accuracy of lung cancer staging, with an accuracy rate of 86% to 90% compared to standalone imaging techniques. Such integration aids in precise tumor characterization and enhances treatment planning and monitoring, enabling clinicians to tailor interventions to individual patient needs. This growing trend presents a significant market opportunity, as healthcare providers increasingly adopt multimodal imaging technologies to improve diagnostic outcomes.

Restraints/Challenges

• Challenges Arising From Regulatory Evolution

The stringent and ever-evolving regulations surrounding healthcare software, particularly in lung cancer screening, create significant barriers for companies attempting to enter the market. Compliance requires rigorous testing, validation, and approval processes, which extend timelines for product development and market launch. Such regulatory demands can result in substantial delays for companies, affecting their ability to introduce new screening software effectively. As a consequence, such challenges may impede growth and hinder innovation within the global lung cancer screening software market, ultimately limiting the availability of advanced diagnostic tools that are crucial for early detection and improved patient outcomes in lung cancer management.

• Overuse of Nasal Sprays

The substantial financial investment needed to integrate advanced lung cancer screening software into existing healthcare systems poses a significant challenge for hospitals and healthcare providers, particularly in regions with limited budgets. For instance, a small rural hospital may face costs exceeding a million USD to implement a comprehensive lung cancer screening program that includes software, training, and necessary hardware upgrades. Such financial burden can deter decision-makers from adopting innovative solutions, leading to delays in implementing essential screening technologies. Consequently, the inability to seamlessly incorporate these advanced lung cancer screening solutions restricts access to early detection and improved patient outcomes and hinders the overall growth of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Lung Cancer Screening Software Market Scope

The market is segmented on the basis of mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

• Cloud Based Solutions
• On-Premise Solutions
• Web Based Solutions

Product

• Lung Cancer Screening Radiology Solution
• Lung Cancer Screening Patient Management Software
•  Nodule Management Software
•  Data Collection and Reporting
•  Patient Coordination and Workflow
•  Lung Nodule Computer Aided Detection
•  Pathology and Cancer Staging
•  Statistical Audit Reporting
•  Screening PACS
•  Practice Management
•  Audit Log Tracking

Type

• Computer-Assisted Screening
•  Traditional Screening

Application

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Platform

• Standalone
• Integrated

Purchase Mode

• Institutional
• Individual

End User

• Oncology Centers
• Hospitals
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Direct Tender
• Third Party Distributors

Lung Cancer Screening Software Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the market and witness significant growth, propelled by several crucial factors. These include the expansion of screening programs, growing adoption of software solutions for efficient patient management, increased demand for screening through chest radiography, and the strong presence of numerous screening centers. Together, these elements highlight North America's dominance in the lung cancer screening software market, underscoring its key role in shaping the industry's future.

Asia-Pacific is expected to be the fastest-growing region in the global lung cancer screening software market. Such growth is driven by a combination of factors, including the increasing incidence of lung cancer, rising awareness about early detection, expanding healthcare infrastructure, and growing investments in advanced diagnostic technologies. In addition, supportive government initiatives and an increasing focus on improving patient outcomes further contribute to the rapid market expansion in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Lung Cancer Screening Software Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Lung Cancer Screening Software Market Leaders Operating in the Market Are:

• Koninklijke Philips N.V. (Netherlands)
• Volpara Health Limited (New Zealand)
• Siemens Healthcare GmbH (Germany)
• MeVis Medical Solutions AG (Germany)
• CANON MEDICAL SYSTEMS EUROPE B.V. (U.S.)
• Medtronic (Ireland)
• FUJIFILM Holdings Corporation (Japan)
• Median Technologies (France)
• Aidence (Netherlands)
• Core Talent and Leadership Development Private Limited (South Korea)
• Oncocyte Corporation (U.K.)

Latest Developments in Lung Cancer Screening Software Market

• In November 2023, Aidence, Incepto, and Thirona jointly launched a clinical solution designed to support the expansion of lung cancer screening across Europe. This collaboration marks a strategic initiative to enhance screening capabilities and drive advancements in the detection and management of lung cancer throughout the continent
• In July 2022, GE Healthcare bolstered its position in the healthcare sector with the launch of the Voluson Expert 22, the most advanced ultrasound in its Women’s Health portfolio. Featuring graphic-based beam former technology, this product delivers superior imaging quality and increased flexibility, reinforcing GE Healthcare’s dedication to offering state-of-the-art products and services to healthcare institutions
• In October 2021, Thynk Health announced a strategic partnership with Infervision, leveraging the world's most advanced technologies to fight lung cancer. This collaboration enhances lung cancer screening and strengthens Thynk Health’s market presence, positioning the company as a leading force in pulmonary nodule management and innovative healthcare solutions

SKU-46081